Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 11/20 | 0.49 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.37 |
| ▸ | FEN1 | P39748 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21384181 | 0.82 | OXTR (0.42) | OXTRAVPR1ATYK2AVPR2ALOX5AP | |
| SCHEMBL30592132 | 0.82 | OXTR (0.42) | OXTRAVPR1ATYK2AVPR2ALOX5AP | |
| SCHEMBL23980125 | 0.79 | OXTR (0.39) | OXTRAVPR1AAVPR2ALOX5APFEN1 | |
| SCHEMBL24498490 | 0.76 | ALOX5AP (0.43) | TYK2ALOX5APFEN1KDM4E | |
| SCHEMBL31106622 | 0.74 | ALOX5AP (0.49) | ALOX5APFEN1 | |
| SCHEMBL25538940 | 0.74 | ALOX5AP (0.39) | OXTRAVPR1AAVPR2ALOX5APFEN1 | |
| SCHEMBL30260644 | 0.73 | KDM4E (0.36) | TYK2MAP4K1KDM4ELMNA | |
| SCHEMBL23980129 | 0.73 | TYK2 (0.44) | TYK2ALOX5APFEN1 | |
| SCHEMBL30260594 | 0.72 | CD274 (0.35) | TYK2ALOX5APFEN1KDM4E | |
| SCHEMBL24498032 | 0.72 | FEN1 (0.44) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479831-B2 | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
| EP-4143180-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | Bristol-Myers Squibb Company (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115715287-A | Substituted N- (methyl-d 3) pyridazine-3-carboxamide or N- (methyl-d 3) -nicotinamide compounds as IL-12, IL-23 and/or IFN alpha modulators | 百时美施贵宝公司 | 2023-02-24 | — | — | CN | disclosed |
| WO-2021222153-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222153-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | JAK3, TYK2, IRAK3 | OXTR 4464/4885AVPR1A 2982/4885TYK2 2/4885 |
| US-12479831-B2 | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators | TYK2, IRAK3, JAK3 | OXTR 4305/4885AVPR1A 2954/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.